Raymond James upgraded Stryker (SYK) to Outperform from Market Perform with a $418 price target The company has been one of the “highest quality compounders” in medical technology for the last five years, but the stock’s forward multiple compressed in 2025, as estimates trended higher, the analyst tells investors in a research note. Raymond James says this does not make sense. Stryker’s current valuation represents an attractive entry point, the firm contends.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.